Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Fluhr Gabriele |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Pieber, TR; Svehlikova, E; Fluhr, G; Höller, V; Gatschelhofer, C; Lackner, B; Magnes, C; Ratzer, M; Jezek, J; Howell, SJ; Gerring, D; Zakrzewski, L; Pillai, V; Murray, S
Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes
DIABETOLOGIA. 2024; 67: S534-S534.-60th Annual Meeting of the EASD; SEP 9-13, 2024; Madrid, SPAIN.
[Poster]
Web of Science
Svehlikova, E; Gatschelhofer, C; Höller, V; Fluhr, G; Lackner, B; Magnes, C; Ratzer, M; Gerring, D; Jezek, J; Howell, SJ; Zakrzewski, L; Pillai, V; Murray, S; Pieber, TR;
AT278 U500–Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart in overweight and obese people with type 2 diabetes.
Wien Klin Wochenschr (2024) . 2024; Supplement 18(136):S720--52. Jahrestagung der Österreichischen Diabetes Gesellschaft; NOV 14-16, 2024; Salzburg, AUSTRIA.
[Oral Communication]
Svehlikova, E; Gatschelhofer, C; Regittnig, W; Fluhr, G; Höller, V; Lackner, B; Eberl, A; Magnes, C; Pieber, TR
Glucagon as a potential promoter of sodium-glucose co-transporter 2 induced ketogenesis via effect on lipolysis
Wien Klin Wochenschr, . 2024; Supplement 18(136):S720--52. Jahrestagung der Österreichischen Diabetes
Gesellschaft; NOV 14-16, 2024; Salzburg, AUSTRIA.
[Oral Communication]
Svehlikova, E; Regittnig, W; Gatschelhofer, C; Höller, V; Fluhr, G; Lackner, B; Magnes, C; Eberl, A; Pieber, TR
Glucagon as a potential promoter of sodium-glucose co-transporter 2 induced ketogenesis via effect on lipolysis
DIABETOLOGIA. 2024; 67: S346-S347.-60th Annual Meeting of the EASD; SEP 9-13, 2024; Madrid, SPAIN.
[Poster]
Web of Science
Svehlikova, E; Regittnig, W; Gatschelhofer, C; Höller, V; Fluhr, G; Lackner, B; Magnes, C; Eberl, A; Pieber, TR
Dapagliflozin reduces endogenous glucose production during a period of acute insulin deprivation and development of ketoacidosis in people with type 1 diabetes
DIABETOLOGIA. 2024; 67: S128-S129.-60th Annual Meeting of the EASD; SEP 9-13, 2024; Madrid, SPAIN.
[Oral Communication]
Web of Science
Svehlikova, E; Regittnig, W; Gatschelhofer, C; Höller, V; Fluhr, G; Lackner, B; Magnes, C; Eberl, A; Pieber, TR
SGLT2 inhibition reduces endogenous glucose production during a period of acute insulin deprivation and development of ketoacidosis in people with type 1 diabetes
Wien Klin Wochenschr. 2024; Supplement 18(136):S721--52. Jahrestagung der Österreichischen Diabetes Gesellschaft; NOV 14-16, 2024; Salzburg, AUSTRIA.
[Oral Communication]
Svehlikova, E; Holler, V; Gumilar, J; Fluhr, G; Urschitz, M; Wolf, M; Lackner, B; Magnes, C; Ratzer, M; Gerring, DJ; Jezek, J; Howell, SJ; Zakrzewski, L; Pillai, V; Ashcroft, N; Lawrence, FJ; Pieber, TR
Phase I study investigating PK and -PD of highly-concentrated insulin aspart AT278 U500
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):262-262.
[Oral Communication]
Web of Science